Mission and Core Values

Partnerships and Community

COMPASS Initiative

Gilead Lift

Gilead HIV Age Positively

TRANScend

HepConnect

Giving

What We Fund

Funding Requests

Gilead Foundation

Gilead Public Health Award

Sustainability

Our Business Is Sustainable

Performance

Reporting

U.N. Global Compact

U.N. Sustainable Development Goals

Advancing Global Health

HCV Elimination

COVID-19

Medication Access

U.S. Patient Access

Disaster Product Replacement

Global Access

Authorized Distributors

Leadership

How We Operate

Governance

Transparency

Ethics and Code of Conduct

Policies

Disclosures

Anti-Counterfeiting

Consumer Product Safety

Supplier Information

Anti-Bribery and Anti-Corruption Policy

Political Contributions

U.S. Locations

Medicines

Pipeline

Research

Compassionate Use

Investigator-Sponsored Research

Clinical Trials Transparency & Data Sharing Policy

Newsroom

Press Releases

Press FAQS

Stories

Company Statements

Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19

Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in Pediatric Patients Hospitalized With COVID-19

Gilead Sciences Statement on Remdesivir Clinical Data

Gilead Sciences Response to U.S. Senators on Trial Diversity

Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study

Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir

Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims

Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China

Gilead Sciences Response to Médecins Sans Frontières

Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak

Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents

Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

Gilead Statement on Commitment to Advancing Descovy for PrEP™ Study in Cisgender Women & Adolescent Females

Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents

Petitions to US Patent and Trademark Office on HIV PrEP Patents

Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy

Grants for SCLAN

Authorized Generics For HCV

Discount For Ambisome

Gilead 2017 Year in Review

100 Corporate Equality Score

Emergency Disaster Response

Gilead Year in Review 2016

Top Corporate Philanthropist

HIV Medicines Reach 10 Million People

Discover Study Of FTAF For PrEP

Corporate Responsibility Report 2015

Gilead Supports PrEP Education

Corporate Contributions Report

Celebrating Transgender Awareness Week

Kite Pharma

Harnessing The Immune System

Events

Annual Report

Year in Review 2019

Now Hiring

Culture

Diversity & Inclusion

Benefits

Internships

Privacy Statements

Cookie Statement

Privacy Shield Covered Entities

Terms Of Use

Social Media Guidelines

Linkedin Guidelines

Twitter Guidelines

EU Data Disclosure

Contact

Request Medicines Information

Information for Suppliers

Partnership Request

North America

Canada

Mexico

USA

South America

Argentina

Brazil

Asia

China

Hong Kong

India

Japan

Korea

Singapore

Taiwan

Middle East

United Arab Emirates

Africa

South Africa

Australia

Australia New Zealand

Europe

Austria

Belgium Luxembourg

Czech Republic & Slovakia

Denmark

Finland

France

Germany

Greece

Iceland

Ireland

Israel

Italy

Netherlands

Norway

Poland & The Baltics

Portugal

Russia

Spain

Sweden

Switzerland

Turkey

United Kingdom